Palatin Technologies News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.02.23	Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update (PR Newswire)
10.02.23	Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023 (PR Newswire)
19.01.23	Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease (PR Newswire)
18.01.23	Palatin Receives $4.7 Million of Non-Dilutive Funding (PR Newswire)
10.01.23	Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions (PR Newswire)
05.01.23	Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results (PR Newswire)
14.11.22	Palatin Technologies Inc. Q1 Loss increases, but beats estimates (RTTNews)
14.11.22	Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update (PR Newswire)
09.11.22	Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022 (PR Newswire)
31.10.22	Palatin Announces $10 Million Registered Direct Offering (PR Newswire)
24.10.22	Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting (PR Newswire)
20.10.22	First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial (PR Newswire)
17.10.22	Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD) (PR Newswire)
13.10.22	Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results (PR Newswire)
29.09.22	Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference (PR Newswire)
29.09.22	Palatin to Participate in Ladenburg Thalmann Healthcare Conference (PR Newswire)
22.09.22	Palatin Technologies Inc. Q4 Loss decreases, but misses estimates (RTTNews)
22.09.22	Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update (PR Newswire)
22.09.22	Pre-market Movers: PRST, KOD, GRVY, BEAT, PULM… (RTTNews)
19.09.22	Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022 (PR Newswire)
08.09.22	Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis (PR Newswire)
19.08.22	Palatin Stock To Begin Trading On Split-Adjusted Basis On Aug. 31 (RTTNews)
19.08.22	Palatin Announces Intent to Effect Reverse Stock Split (PR Newswire)
16.08.22	Palatin Announces Positive Study Results For Its Drug To Treat Dry Eye Disease (RTTNews)
16.08.22	Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease (PR Newswire)
26.07.22	Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter (PR Newswire)
17.05.22	Palatin Technologies Inc. Q3 loss increases in line with estimates (RTTNews)
17.05.22	Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update (PR Newswire)
12.05.22	Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock (PR Newswire)
11.05.22	Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022 (PR Newswire)
02.05.22	Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference (PR Newswire)
21.04.22	Palatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022 (PR Newswire)
03.03.22	Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease (PR Newswire)
15.02.22	Palatin Technologies Inc. Q2 Loss misses estimates (RTTNews)
15.02.22	Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update (PR Newswire)
10.02.22	Palatin to Report Second Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on February 15, 2022 (PR Newswire)
21.01.22	Palatin: Pre-clinical Data Show Positive Effects Of Melanocortins For Ulcerative Colitis (RTTNews)
21.01.22	Palatin Announces Presentation at the 2022 Crohn's and Colitis Congress (PR Newswire)
07.01.22	Palatin to Present at H.C. Wainwright BioConnect Conference (PR Newswire)
28.12.21	Palatin Advances PL9643 For The Treatment Of Dry Eye Disease Into Phase 3 Study (RTTNews)
28.12.21	Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease (PR Newswire)
07.12.21	Pre-market Movers: BJDX, MDB, CELZ, ISIG, ACAD… (RTTNews)
02.12.21	Pre-market Movers: TANH, GRAB, DWAC, VIR, SNOW… (RTTNews)
30.11.21	Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptide (PR Newswire)
15.11.21	Palatin Technologies Inc. Q1 Earnings Summary (RTTNews)
15.11.21	Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update (PR Newswire)
10.11.21	Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021 (PR Newswire)
22.10.21	Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting (PR Newswire)
29.09.21	Palatin Posts Wider Loss In Q4 - Quick Facts (RTTNews)
29.09.21	Palatin Technologies Inc. Q4 Earnings Summary (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

14.02.22		Ausblick: Palatin Technologies präsentiert Bilanzzahlen zum jüngsten Jahresviertel
14.11.21		Ausblick: Palatin Technologies präsentiert Quartalsergebnisse

14.02.22

Ausblick: Palatin Technologies präsentiert Bilanzzahlen zum jüngsten Jahresviertel

14.11.21

Ausblick: Palatin Technologies präsentiert Quartalsergebnisse

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Palatin Technologies Inc

Aktien Top/Flop

Palatin Technologies Peer Group Nachrichten

Meistgelesene Nachrichten